Skip to main content
ADHERIUM LIMITED logo

ADHERIUM LIMITED — Investor Relations & Filings

Ticker · ADR ISIN · AU000000ADR1 ASX Manufacturing
Open in API
Filings indexed 878 across all filing types
Latest filing 2015-12-17 Fund Information / Fact…
Country AU Australia
Listing ASX ADR

About ADHERIUM LIMITED

https://www.adherium.com

Adherium Limited is a digital health company specializing in the development and commercialization of connected medical devices and software solutions for chronic respiratory management. The company's primary offering is the Hailie® platform, which consists of advanced sensors that attach to various inhaler medications to monitor usage and technique. These sensors transmit data via Bluetooth to a mobile application and a cloud-based portal, providing patients and healthcare providers with real-time insights into medication adherence and respiratory health trends. By facilitating remote patient monitoring and data-driven clinical decisions, Adherium aims to improve health outcomes for individuals living with asthma and chronic obstructive pulmonary disease (COPD). The platform is utilized by healthcare systems, pharmaceutical companies, and clinical research organizations to enhance patient engagement and optimize treatment efficacy.

Recent filings

Filing Released Lang Actions
Adherium Shareholder Update 5 pages 2.6MB
Fund Information / Factsheet Classification · 90% confidence The document is titled 'Adherium Shareholder Update December 2015' and is dated 18 December 2015. It is a 5-page update to shareholders highlighting company progress since its IPO in August 2015. The content includes business updates, new projects, commercial partnerships, clinical data, certifications, new registered designs, and a new board member introduction. It does not contain detailed financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It also does not appear to be a transcript, audit report, or regulatory filing. The document is a shareholder update, which is a form of investor communication but not a formal investor presentation or earnings release. Given the nature of the content and the length, it fits best as a Shareholder Update, which aligns most closely with the Fund Information / Factsheet (FS) category, as it provides a brief summary of key company facts, financials, and market info in a concise format. Therefore, the classification is FS with high confidence.
2015-12-17 English
William (Bill) Hunter MD to Join Adherium Board of Directors 3 pages 133.5KB
Board/Management Information Classification · 100% confidence The document is an announcement dated December 16, 2015, from Adherium Limited regarding the appointment of Dr. William (Bill) Hunter MD to the company's board as a non-executive director. It includes biographical details about Dr. Hunter and his professional background, as well as information about the company and its products. There are no financial statements, regulatory filings, or detailed reports included. The content focuses solely on a change in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 6188 characters, which is sufficient for a full announcement rather than a brief notice or report publication announcement.
2015-12-15 English
Appendix 3B - Release of Restricted Securities 14 pages 699.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to new securities issuance and quotation. It contains detailed information about securities issued, classes of securities, issue prices, and quotation requests. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding new issues or changes in securities, including restricted securities and their release from escrow. It does not contain financial statements or comprehensive financial performance data, nor is it a report or presentation. It is clearly an announcement related to capital changes, specifically new issue announcements and applications for quotation of additional securities. Therefore, the document fits the category of Capital/Financing Update (CAP).
2015-12-13 English
Release of Restricted Securities from Escrow 1 page
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement from Adherium Limited regarding the release of restricted securities from escrow as per ASX Listing Rule 3.10A. It specifies the number of shares being released from restriction and the date of release. There is no financial data, no detailed report, and no mention of a meeting or voting results. The document is brief (under 5,000 characters) and serves as a regulatory announcement about share capital restrictions being lifted. This fits the category of Share Issue/Capital Change (SHA) because it relates to changes in share capital status (release from escrow restrictions).
2015-11-26 English
Appendix 4C - quarterly 7 pages 399.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Quarterly Cash Flow Report to 30 September 2015" and includes detailed financial data such as consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. It is explicitly described as a quarterly update and cash flow report, with reference to Appendix 4C, which is a standard quarterly report format for entities admitted on the basis of commitments on the ASX. The document contains substantive financial data and analysis for a quarter ended 30 September 2015, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2015
2015-10-28 English
New Clinical Data Presented at ERS 2015 4 pages 212.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Adherium Limited dated 30 September 2015, presenting new independent clinical data on their Smartinhaler platform. It summarizes results from three independent clinical studies presented at a conference (European Respiratory Society International Congress). The document is relatively short (4 pages, 9033 characters) and focuses on clinical study outcomes and company overview rather than financial data or regulatory filings. There is no indication of financial statements, management discussion, or regulatory compliance content. It is not a full report but an announcement of clinical data and study results. Therefore, it does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or governance document. The best fit is Regulatory Filings (RNS) as a general announcement of clinical data and company news that does not fit other categories.
2015-09-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.